Trial Outcomes & Findings for A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma (NCT NCT00479167)
NCT ID: NCT00479167
Last Updated: 2021-11-04
Results Overview
Recruitment status
TERMINATED
Study phase
PHASE2
Target enrollment
1 participants
Primary outcome timeframe
Study terminated.
Results posted on
2021-11-04
Participant Flow
Participant milestones
| Measure |
Bortezomib in Combination With Tositumomab
|
|---|---|
|
Overall Study
STARTED
|
1
|
|
Overall Study
COMPLETED
|
0
|
|
Overall Study
NOT COMPLETED
|
1
|
Reasons for withdrawal
| Measure |
Bortezomib in Combination With Tositumomab
|
|---|---|
|
Overall Study
Withdrawal by Subject
|
1
|
Baseline Characteristics
A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
Baseline characteristics by cohort
Baseline data not reported
PRIMARY outcome
Timeframe: Study terminated.Population: Subject withdrew
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Study Terminated.Population: Subject withdrew
Outcome measures
Outcome data not reported
Adverse Events
Bortezomib in Combination With Tositumomab
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place